
Clinical TrialJul 7, 2026, 08:17 AM
Theriva Biologics gets Spanish approval for VIRAGE2 trial
AI Summary
Theriva Biologics announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the initiation of its VIRAGE2 clinical trial. This Phase IIa, single-arm, open-label study will evaluate increased frequency dosing of zabilugene almadenorepvec (VCN-01) in combination with standard chemotherapy for newly-diagnosed metastatic pancreatic cancer. The trial aims to build on previous positive results from the VIRAGE Phase 2b trial, which showed improved survival with two doses of VCN-01, and will inform the dosing regimen for a future pivotal Phase 3 trial.
Key Highlights
- Spanish Agency of Medicines and Medical Devices (AEMPS) authorized VIRAGE2 clinical trial.
- VIRAGE2 is a Phase IIa trial evaluating increased frequency dosing of VCN-01.
- The trial targets newly-diagnosed metastatic pancreatic cancer patients.
- It combines VCN-01 with gemcitabine/nab-paclitaxel standard-of-care chemotherapy.
- VIRAGE2 builds on VIRAGE Phase 2b results, where 2 doses of VCN-01 improved survival.
- The trial aims to assess feasibility of administering at least 3 doses of VCN-01 two months apart.
- Results will inform the VCN-01 dosing regimen for a future pivotal Phase 3 clinical trial.
Price Impact
More from TOVX